source
- Roche reaffirms sales outlook despite weaker Xolair sales and looming generic competitionRoche reported third-quarter group sales of 16.1 billion Swiss francs, about $19.6 billion, a 7% increase that beat analysts' consensus estimate of 15.8 billion francs. The beat was helped by a ne…
- Medrio aims to unify clinical trial tools to ease complexity for biotech firmsMike Novotny, founder and CEO of Medrio, says that funding cycles, growing study complexity and fragmented technology are slowing clinical research, especially for small and midsize life‑science co…